Bio-Techne Corporation
TECH | NASDAQ
$72.68
+$0.02 (+0.03%)
Nov 2, 2026, 1:15 PM ET · Market open
Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Key Executives
| Name | Position |
|---|---|
| Kim Kelderman | Chief Executive Officer, President & Director |
| Gary J. Latham | Vice President & Chief Technology Officer |
| James T. Hippel | Executive Vice President of Finance & Chief Financial Officer |
| Cheryl Bethune | Senior Vice President & Chief Human Resources Officer |
| David Clair | Vice President of Investor Relations |
| Gerry Andros | Vice President of Sales and Marketing |
| Luca Cicchetti | Managing Director |
| Martin Wirtz | Senior Vice President of Strategy & Corporate Development |
| Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer |
| Steve Crouse | President of Diagnostics & Spatial Biology Segment |
| William A. Geist | President of Protein Sciences Segment |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 30, 2026 | 4 | Filing |
| Sep 24, 2026 | 4 | Filing |
| Sep 23, 2026 | 8-K | Current Report |
| Sep 14, 2026 | DEFA14A | Filing |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 09, 2026 | DEFA14A | Filing |
| Sep 02, 2026 | DEFA14A | Filing |
| Aug 25, 2026 | DEFA14A | Filing |
| Aug 24, 2026 | 10-K | Annual Report |
| Aug 20, 2026 | DEFM14A | Filing |
Bio-Techne Corporation
| Country | United States |
| IPO Date | Feb 9, 1989 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3,000 |
| CEO | Kim Kelderman |
Contact Details
614 McKinley Place N.E. Minneapolis,
Minnesota 55413 United States
Stock Details
| Ticker Symbol | TECH |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0000842023 |
| CUSIP Number | 09073M104 |
| ISIN Number | US09073M1045 |
| SIC Code | 2836 |
Recent News
- 9 hours ago / zacks.comBio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
- 21 days ago / globenewswire.comPress release: CMB.TECH fleet update
- 25 days ago / globenewswire.comCMB.TECH SPECIAL GENERAL MEETING RESULTS
- 1 month ago / prnewswire.comINTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE
- 1 month ago / newsfilecorp.comZhibao Technology Signs Definitive Agreement to Acquire NEXSYS TECH for Planned AI Computing Infrastructure Business
- 1 month ago / prnewswire.comBio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
- 1 month ago / prnewswire.comBio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
- 2 months ago / zacks.comWhy Is Techne (TECH) Down 0.1% Since Last Earnings Report?
- 2 months ago / seekingalpha.comCMB.TECH: Updates From Our Top Shipping Pick Of 2026
- 2 months ago / globenewswire.comPRESS RELEASE: CMB.TECH announces special general meeting on 8 October 2026
Add to Watchlist
Select watchlists to add or remove TECH